MARKET WIREStockInvest.us • 1d ago
Omeros Stock Price Forecast. Should You Buy OMER?StockInvest.us report covering Omeros Corporation (OMER) market action, institutional positioning, and fundamental catalysts.
Why OMER Stock dropped -3.31% Today — RQD Quant Desk Flash
$17.83 -3.31% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $17.69
Omeros Corporation (OMER) carries a Roarable Rating of D- (Sell) with 41/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • RED ALERT
Cap $1.33B
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on OMER Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is OMER stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Omeros Corporation (NASDAQ: OMER) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 41/100 at a spot price of $17.83 (-3.31% 1D, market cap $1.33B). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 11/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 11/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, OMER ranks #436 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does OMER compare to NKTR and DMRA in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), OMER carries a Roarable D- (41/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, NKTR (Nektar Therapeutics) holds a E grade (20/100 RQD, P/E N/A, ROIC -35.0%, cap $1.33B) and DMRA (Damora Therapeutics Inc.) posts a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $1.33B). Among the 5-stock peer group, OMER leads on earnings multiple (N/A) while OMER leads on capital efficiency (-35.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for OMER?
▼
Per OMER's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001285819), Omeros Corporation generated $343.8M in revenue (-26.4% YoY), $0 in net income, and -$116.2M in free cash flow against $325.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $17.69 (-0.79%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (41/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.2% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • D-
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR RQD RADARRw E · Rk D+
Each axis scored 0–20
12M PRICE TARGET CONE-7.6% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for OMER)Realized 20D OHLCV Swing Band: ±10.7%
Deterministic 5-Pillar Attribution (41/100 Composite)
🔍 WHY OMER SCORES 41/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+11/20 pts (27% of score)
20D Institutional Volume Accumulation (±10.7% realized swing band)
▲ #2 Bullish Driver: Macro Regime Fit+11/20 pts (27% of score)
FRED Regime × Technicals: 77% of 52W Range • RSI-14 at 52.9 (NEUTRAL RANGE)
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$18.88-12.3% Next Q
49
Q2 (-2Q)Grade D$16.55+5.7% Next Q
46
Q3 (-1Q)Grade D$17.49+1.9% Next Q
44
CurrentGrade D-$17.83-7.2% Hist 90D α
41
Trajectory: D (49) → D- (41)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a OMER Turnaround Squeeze
While OMER currently carries a cautious 41/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($18.50) and Max Pain ($18.72) forces dealer call-delta covering toward $22.30.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $OMER• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “OMER Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why OMER Stock dropped -3.31% Today — RQD Quant Desk Flash
Omeros Corporation (OMER) dropped -3.31% to $17.83, trading at 77% of its 52-week range ($6.24 – $21.24). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 77% of its 52-week range ($6.24 – $21.24) with RSI-14 at 52.9 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±10.7% around $17.83 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live OMER Headlines & Catalysts
CATALYSTYahoo Finance • 1d ago
Update: Omeros Shares Fall After Narsoplimab Application Rejected Again by EU AgencyYahoo Finance report covering Omeros Corporation (OMER) market action, institutional positioning, and fundamental catalysts.
CATALYSTStocktwits • 1d ago
OMER Stock Surges 5% After Hours On Novo Nordisk Deal Windfall And Drug Launch OptimismStocktwits report covering Omeros Corporation (OMER) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESeeking Alpha • 1d ago
Omeros: The Trade After European Rejection (NASDAQ:OMER)Seeking Alpha report covering Omeros Corporation (OMER) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingView • 2d ago
Omeros Corporation Estimates – NASDAQ:OMERTradingView report covering Omeros Corporation (OMER) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 2d ago
Omeros shares slide following European regulatory setback for NarsoplimabYahoo Finance report covering Omeros Corporation (OMER) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 2d ago
A U.S.-approved drug for a transplant complication gets a negative opinion from Europe's medicines panel.Stock Titan report covering Omeros Corporation (OMER) market action, institutional positioning, and fundamental catalysts.
MARKET WIREFinancialContent • 2d ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMERFinancialContent report covering Omeros Corporation (OMER) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESeekingAlpha • 14d ago
Omeros: The Trade After European RejectionOmeros Corporation is positioned to dominate the TM-TMA market with Yartemlea, the only FDA-approved therapy for this indication. See why I rate OMER stock a hold.
MARKET WIREYahoo • 18d ago
Sector Update: Healthcare Stocks Softer Late AfternoonHealthcare stocks were lower late Friday afternoon, with the NYSE Healthcare Index down 0.1% and the
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring OMER)
- ✓Walkthrough of OMER's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
OMER // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +19.58%🛡️ HOLDING TREND SUPPORT
2026-11-03O $18.95H $18.95L $17.83C $17.83VOL 885.6K
RES: $20.53SUP: $17.11SMA50: $18.50SMA200: $13.55
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
OMER Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth
vs. -26.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on OMER today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for OMER. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for OMER today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (OMER)
Health Care Rank #436 of 1015
⚔️ NKTR vs OMER Full Matrix →
1. Head-to-Head Health Care Peer Comparison (OMER vs. NKTR, DMRA, KARD, AAPG)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, Omeros Corporation (OMER) ranks #436 by composite RQD confidence (41/100, grade D-) and #315 by equity capitalization ($1.33B). Within this direct 5-issuer industry benchmark cohort, OMER leads on earnings valuation at N/A trailing P/E, while OMER leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. KARD currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with OMER at 41/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| OMER
ACTIVE
Omeros Corporation | D- | 41/100 | — | — | -35.0% | -3.31% | $1.33B | Benchmark Subject |
| NKTR Nektar Therapeutics | E | 20/100 | — | 96.0% | -35.0% | -4.94% | $1.33B | /nktr-vs-omer → |
| DMRA Damora Therapeutics Inc. | D- | 35/100 | — | — | -35.0% | +0.51% | $1.33B | /dmra-vs-omer → |
| KARD Kardigan Inc. | D | 46/100 | — | — | — | +0.57% | $1.32B | /kard-vs-omer → |
| AAPG Ascentage Pharma Group International American Depository Shares | D | 45/100 | — | — | — | -6.20% | $1.35B | /aapg-vs-omer → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2024–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001285819 ↗In its most recent audited fiscal period (FY2025, filed 2025-12-31), Omeros Corporation (OMER) reported GAAP revenue of $343.8M (-26.4% vs. FY2024 revenue of $467.5M ) , GAAP net income of $0, operating cash flow of -$116.1M, and free cash flow of -$116.2M (+22.0% YoY). On the balance sheet, OMER closed FY2025 with $325.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $343.8M | $0 | -$116.1M | -$116.2M | $325.6M | — |
| FY2024 (FY) | 2024-12-31 | $467.5M | $0 | -$148.8M | -$149.0M | $277.1M | — |
3. OMER Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs OMER stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Omeros Corporation (NASDAQ: OMER) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 41/100 at a spot price of $17.83 (-3.31% 1D, market cap $1.33B). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 11/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 11/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, OMER ranks #436 in composite RQD confidence.
How does OMER compare to NKTR and DMRA in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), OMER carries a Roarable D- (41/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, NKTR (Nektar Therapeutics) holds a E grade (20/100 RQD, P/E N/A, ROIC -35.0%, cap $1.33B) and DMRA (Damora Therapeutics Inc.) posts a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $1.33B). Among the 5-stock peer group, OMER leads on earnings multiple (N/A) while OMER leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for OMER?
Per OMER's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001285819), Omeros Corporation generated $343.8M in revenue (-26.4% YoY), $0 in net income, and -$116.2M in free cash flow against $325.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Where is OMER trading relative to its 50-day, 200-day, and 52-week technical levels?
OMER last traded at $17.83 (-3.31% on volume of 903,526 shares), positioning the stock -3.62% below its 50-day simple moving average ($18.50) and +31.59% above its 200-day simple moving average ($13.55). Across its 52-week range of $6.24 to $21.24, OMER sits at the 77.3% percentile with a 14-day RSI of 52.9 (NEUTRAL RANGE) and an implied next-earnings move of ±10.7% ($15.92 to $19.74).
ROARABLE RATING BRIEF • RQD 41/100 (D-)
✓ SEC XBRL & RQD VERIFIED
OMER — Omeros Corporation: What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31
1. Roarable Rating Brief: What This Means to a Prospective Investor
Omeros Corporation (OMER) earns a live Roarable RQD composite score of 41/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $17.83 (-3.31% 1D, market capitalization $1.33B).
- Fundamental Cash Engine (6/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of -8.47%.
- Whale 13F & Options Flow (11/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (11/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 1/9, and Debt/Equity of N/A.
2. Business Model, Unit Margins & SEC Financial Trajectory
Omeros Corporation (OMER) is a NASDAQ-listed issuer classified under the Health Care sector and the Biotechnology: Pharmaceutical Preparations industry..4B. Revenue is reported as — in the SEC financials for both FY 2025 and FY 2024.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Omeros Corporation (OMER) reported $343.8M in annual revenue (up from $467.5M in FY2024, -26.4% YoY) and $0 in GAAP net income. Over the multi-year SEC filing window from FY2024 ($467.5M revenue, $0 net income) through FY2025, OMER scaled operating cash flow to -$116.1M and free cash flow to -$116.2M, backed by $325.6M in total assets against $0 in total debt.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (D- • RQD 41/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -8.47% and institutional whale pillar of 11/20. With Fundamental Cash Engine at 6/20 and Institutional Whale Flow at 11/20, sustained execution supports upside toward the upper end of the $6.24 – $21.24 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
— supply_chain is NONE, butterfly_links is empty, and no proprietary signals are present. Upstream and downstream dependencies, sector correlations, and 2nd-order bottlenecks cannot be established from the source data.
- Key Question #1: Can OMER sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
- Key Question #2: Following FY2025 revenue of $343.8M and free cash flow of -$116.2M, how will capital allocation balance growth reinvestment against $0 in total debt?
- Key Question #3: How sensitive is OMER's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?
OMER Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Omeros Corporation (OMER) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE StockInvest.us • 1d ago
Omeros Stock Price Forecast. Should You Buy OMER? StockInvest.us report covering Omeros Corporation (OMER) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Yahoo Finance • 1d ago
Update: Omeros Shares Fall After Narsoplimab Application Rejected Again by EU Agency Yahoo Finance report covering Omeros Corporation (OMER) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Stocktwits • 1d ago
OMER Stock Surges 5% After Hours On Novo Nordisk Deal Windfall And Drug Launch Optimism Stocktwits report covering Omeros Corporation (OMER) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Seeking Alpha • 1d ago
Omeros: The Trade After European Rejection (NASDAQ:OMER) Seeking Alpha report covering Omeros Corporation (OMER) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingView • 2d ago
Omeros Corporation Estimates – NASDAQ:OMER TradingView report covering Omeros Corporation (OMER) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 2d ago
Omeros shares slide following European regulatory setback for Narsoplimab Yahoo Finance report covering Omeros Corporation (OMER) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 2d ago
A U.S.-approved drug for a transplant complication gets a negative opinion from Europe's medicines panel. Stock Titan report covering Omeros Corporation (OMER) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE FinancialContent • 2d ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER FinancialContent report covering Omeros Corporation (OMER) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
OMER Bull vs. Bear Conversation Board — What's Your Call at $17.83?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON OMER 🐻 33% BEARISH CONVICTION
AL AlphaFlow_Cap RQD DEBATE OPENER • Verified $100K Arena Trader 🐂 BULLISH
🎯 Target: $21.94 (+19.0%)
📌 Pinned Debate Whale 13F Flow scores 16 of 20, the strongest RQD pillar, showing institutional accumulation and options positioning despite weak funda
Don't sleep on OMER's setup in Health Care. Whale 13F Flow scores 16 of 20, the strongest RQD pillar, showing institutional accumulation and options positioning despite weak fundamentals.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (41/100) backs up the fundamental quality.
EarningsSniper 🐂 BULL
@RedlineAuditor Shorting a 11/20 institutional whale-flow stock at $18.44 is dangerous when funds are rotating into Health Care.
RE RedlineAuditor RQD DEBATE OPENER • Accounting Quality Watch 🐻 BEARISH
🎯 Target: $13.83 (-25.0%)
Spot @ $18.44 ROIC of -35% and FCF yield of -8.47% alongside Piotroski F 1/9 show a company consuming cash with weak financial quality.
Sitting on the sidelines or leaning short OMER above $18.44. ROIC of -35% and FCF yield of -8.47% alongside Piotroski F 1/9 show a company consuming cash with weak financial quality.. Until Fundamental Cash Engine (6/20) and FCF yield (-8.47%) inflect higher, upside is capped near $21.24.